Cogent Biosciences, Inc.
COGT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001622229
In the last 90 days, Cogent Biosciences, Inc. insiders filed 0 open-market purchases and 1 sale; 335 institutions reported holding it in 13F filings for Q2 2026, worth $7.82B in total; Oaktree Capital is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Cogent Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $1.69M in total
- Insiders trading
- 1
- Net value
- −$1.69M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Cogent Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Morris Arlene | Director | 0 | Aug 31, 2026 | 2 |
| Ferrante Karen Jean | Director | – | Jul 6, 2026 | 5 |
| Harwin Peter Evan | Director | – | Jun 11, 2026 | 1 |
| Ros Matthew | Director | – | Jun 11, 2026 | 1 |
| Shegog Todd | Director | – | Jun 11, 2026 | 1 |
| Cain Christopher W. | Director | – | Jun 11, 2026 | 1 |
| Robbins Andrew R | President and CEO | 160,000Indirect | May 21, 2026 | 2 |
| Fairmount Funds Management LLC | Director | 5,503,418Indirect | Mar 31, 2026 | 2 |
| Green John L. | Chief Financial Officer | 131,834 | Dec 30, 2025 | 2 |
| Kearns Evan | Chief Legal Officer | 109,398 | Dec 30, 2025 | 2 |
| Sachs Jessica | Chief Medical Officer | 133,938 | Dec 30, 2025 | 2 |
| Robinson John Edward | Chief Scientific Officer | 140,002 | Dec 30, 2025 | 2 |
| Pinnow Cole | Chief Commercial Officer | 216,650 | Dec 19, 2025 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 31, 2026 (view filing)5:01 PM ET | Aug 27 | 4 days | Morris ArleneDirector | SSale | −45.5K | $37.12 | −$1.69M | −100.0%0 after | 2 lots10b5-1 |
| Mar 31, 2026 (view filing) | Mar 31 | Same day | Fairmount Funds Management LLCDirector | SSale | −7.00M | $34.66 | −$242.6M | −56.0%5.50M after | |
| Jan 22, 2026 (view filing) | Jan 22 | Same day | Fairmount Funds Management LLCDirector | SSale | −3.50M | $36.40 | −$127.4M | −38.9%5.50M after | |
| Dec 30, 2025 (view filing) | Dec 26 | 4 days | Kearns EvanChief Legal Officer | SSale | −65.0K | $38.70 | −$2.52M | −37.3%109.4K after | |
| Dec 30, 2025 (view filing) | Dec 26 | 4 days | Green John L.Chief Financial Officer | SSale | −77.0K | $38.68 | −$2.98M | −36.9%131.8K after | |
| Dec 30, 2025 (view filing) | Dec 26 | 4 days | Sachs JessicaChief Medical Officer | SSale | −82.6K | $38.70 | −$3.20M | −38.2%133.9K after | |
| Dec 30, 2025 (view filing) | Dec 26 | 4 days | Robinson John EdwardChief Scientific Officer | SSale | −90.0K | $38.74 | −$3.49M | −39.1%140.0K after | |
| Jul 14, 2025 (view filing) | Jul 10 | 4 days | Fairmount Funds Management LLCDirector | PPurchase | +2.78M | $9.00 | +$25.0M | +44.6%9.00M after | |
| Jan 15, 2025 (view filing) | Jan 14 | 1 day | Pinnow ColeChief Commercial Officer | PPurchase | +43.8K | $7.60 | +$332.5K | +2,085.3%45.8K after | |
| Jun 13, 2023 (view filing) | Jun 9 | 4 days | Fairmount Funds Management LLC10% Owner, Other: See Remarks | PPurchase | +800.0K | $12.00 | +$9.60M | +32.4%3.27M after | |
| Jun 21, 2022 (view filing) | Jun 16 | 5 days | Fairmount Funds Management LLC10% Owner, Other: See Remarks | PPurchase | +1.20M | $8.25 | +$9.90M | +94.3%2.47M after |